Abstract 780
Background
The adipose cell is reported to impact the biological activities of breast cancer cells. Simultaneously, circular RNAs are novel non-coding RNAs abundantly detected in mammalian cells. Recently, hsa_circ_0000190 was found to be a non-invasive biomarker in the diagnosis of gastric cancer. However, the function of hsa_circ_0000190 in breast cancer cells under the effects of the adipocyte was unknown. In this study, we aimed to investigate the role of adipose in regulating the hsa_circ_0000190 expression of breast cancer cells.
Methods
The expression level of hsa_circ_0000190 was identified in HPA-v adipose cells, MDA-MB-231 and MCF-7 breast cancer cells through quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Wound healing, migration and invasion assay were performed. Luciferase Assay System were used to detect harbored miRNA.
Results
After cocultured with HPA-v adipose cells, the invasion and migration of breast cancer cells were obviously promoted. Then compared with HPA-v adipose cell line, the expression of circ_0000190 was 1.27-fold in MCF-7 breast cancer cell line. Also, the expression of circ_0000190 in MCF-7/CM was down-regulated 0.71 than that in MCF-7 cells (P<0.05) . Mechanically, the expression of hsa_circ_0000190 in MDA-MB-231 was significantly down-regulated 0.25 comparing to MCF-7 (P<0.05). Overexpression of hsa_circ_0000190 in MDA-MB-231 could obviously suppress invasion and migration of breast cancer cells (P<0.05) , while silencing of it in MCF-7 could promote invasion and migration (P<0.05) . MiR-135b functioned as a tumor promoter gene, and it could be captured by hsa_circ_0000190 (P<0.05).
Conclusions
The results revealed that adipocytes could deteriorate the prognosis of breast cancer cells and hsa_circ_0000190 could be a potentially novel biomarker for the non-invasive breast cancer. In details, adipocytes might depress the role of hsa_circ_0000190 in suppressing invasion and metastasis of breast cancer by capturing miR-135b.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Jinhai Tang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.